On Tuesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Synthetic Biologics Inc. (NYSEMKT:SYN), Science Applications International Corporation (NYSE:SAIC), Gevo, Inc. (NASDAQ:GEVO), Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Synthetic Biologics Inc. (NYSEMKT:SYN), with shares declined -4.37%, closed at $2.19.
Science Applications International Corporation (NYSE:SAIC), with shares dropped -7.81%, settled at $51.35.
Gevo, Inc. (NASDAQ:GEVO), with shares dipped -5.37%, and closed at $0.2010.
Pacific Biosciences of California, Inc. (NASDAQ:PACB), plummeted -5.81%, and closed at $5.84.
Latest NEWS regarding these Stocks are depicted underneath:
Synthetic Biologics Inc. (NYSEMKT:SYN)
Synthetic Biologics Inc. (SYN), declared the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Corporation’s investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). C. difficile is the leading type of hospital attained infection and is frequently associated with intravenous (IV) antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection administration, and comprise ordinarily used penicillin and cephalosporin antibiotics, such as ceftriaxone.
“We are excited to start our Phase 2a trial of SYN-004 on plan. Synthetic Biologics believes SYN-004 holds the potential to protect the microbiome from the damaging effects of antibiotics and dramatically reduce C. difficile infections through prevention vs. treatment,” said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. “We anticipate reporting topline results from this Phase 2a clinical trial during the second quarter of 2015, and initiating the Phase 2b clinical trial in the second half of this year.”
Synthetics Biologics, Inc., a biotechnology corporation, focuses on development of novel anti-infective biologics and drug candidates targeting specific pathogens that cause serious infections and other diseases.
Science Applications International Corporation (NYSE:SAIC)
Science Applications International Corporation (SAIC), declared financial results for the fourth quarter and fiscal year ended January 30, 2015. SAIC commenced its operations on September 27, 2013 (during the third quarter of fiscal year 2014) following completion of a spin-off transaction from its former parent. As formerly declared, SAIC has reached a definitive contract to purchase Scitor Holdings, Inc. and the transaction is predictable to close in May 2015.
Total proceeds for the fourth quarter were $952 million contrast to $941 million during the fourth quarter of the preceding year. Total proceeds expanded from the preceding year due to raised material volume on supply chain contracts and from proceeds on newly awarded programs. These raises offset lower proceeds caused by the continued influence of programs that ended in the preceding year and lower activity on in-theater logistics programs.
Total proceeds for the fiscal year were $3.89 billion ($3.84 billion not including proceeds performed by former parent), contrast to $4.12 billion during the preceding year ($4.02 billion not including proceeds performed by former parent). The contraction in proceeds is the result of the continued influence of programs that ended in the preceding year, counting DISN Global Solutions (DGS), an Army Reserve and National Guard technical support program, and lower activity on in-theater logistics programs. These decreases were partially offset by proceeds on newly awarded programs and raised material volume on supply chain contracts.
Science Applications International Corporation, a technology integrator, provides full life-cycle services and solutions in technical, engineering, and enterprise information technology (IT) markets in the United States.
Gevo, Inc. (NASDAQ:GEVO)
Gevo, Inc. (GEVO), declared its financial results for the three months ended December 31, 2014 and offered an update on recent corporate highlights.
In the fourth quarter of 2014, Gevo continued to progress the commercial operation of isobutanol at Luverne under the Side-by-Side mode of production (SBS), meeting its stated milestone in December 2014 of producing greater than fifty thousand gallons of isobutanol in one month. This achievement was a result of the introduction of Gevo’s second-generation yeast biocatalyst at the plant, in addition to noteworthy process improvements learned by Gevo since switching the plant to SBS production earlier in 2014.
The data generated at the Luverne plant and in the labs in Denver continues to support ultimate, optimized isobutanol production costs that would support EBITDA margins for isobutanol of $0.50-$1.00 per gallon. In the fourth quarter, Praj Industries Limited (Praj), a global leader in process engineering and equipment manufacturing for the ethanol and brewing industries, conducted extensive due diligence at the Luverne plant, and has confirmed these cost projections. Praj has subsequently signed a memorandum of understanding (MOU) wherein Praj will undertake to license up to 250 million gallons of isobutanol capacity for sugar-based ethanol plants over the next ten years.
With this data in hand, Gevo’s focus has turned to the licensing of its isobutanol technology. In addition to the Praj MOU, Gevo signed a letter of intent (LOI) in the fourth quarter to license its technology to Highland EnviroFuels’ sugar cane and sweet sorghum project based in Florida. These supplement the LOIs that were formerly reached with IGPC Ethanol Inc. based in Canada, and Porta Hnos S.A. based in Argentina. As a result of this interest, Gevo is targeting signing a binding contract with at least one licensee for its isobutanol technology in 2015.
Gevo, Inc., a renewable chemicals and biofuels corporation, focuses primarily on the production and sale of isobutanol and related products from renewable feedstocks. Isobutanol is a four-carbon alcohol, which is used as a specialty chemical in the production of solvents, paints, and coatings or as a value-added gasoline blendstock.
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Formerly on March 23, Pacific Biosciences of California, Inc. (PACB), declared that the corporation has launched a Certified Service Provider (CSP) program and added new informatics partners to meet the increasing demand for Single Molecule, Real-Time (SMRT(R)) Sequencing and data analysis worldwide. The PacBio CSP program is a global network of validated service organizations utilizing PacBio’s sequencing technology. PacBio CSPs undergo a standardized certification procedure in order to ensure they are capable of delivering the highest-quality data to their clients.
The first service providers to be certified are:
- DNA Link, Inc., based in Korea
- GATC Biotech AG, based in Germany
- McGill University and Genome Quebec Innovation Centre
- Takara Bio Inc., based in Japan
- Washington State University, Molecular Biology and Genomics Core
- Arizona Genomics Institute, University of Arizona, Tucson
“We have seen great demand for SMRT Sequencing in Korea and abroad, and are now running more SMRT Cells than flow cells or chips from any other sequencing platform,” said Gun-Eui Lee, Chief Technology Officer of DNA Link. “Once customers experience the benefits of PacBio long reads, they especially prefer this technology for de novo sequencing.”
Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The corporation provides single molecule real-time (SMRT) technology platform, which enables single molecule real-time detection of biological processes.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
